1. Errata : ocena kadrovskih potreb za izvajanje zdravljenja raka v Republiki SlovenijiKatarina Lokar, Marjana Bernot, Maja Ebert Moltara, Mateja Marc-Malovrh, Radivoje Pribaković Brinovec, Brigita Skela-Savič, Vesna Zadnik, Tina Žagar, Branko Zakotnik, 2021, other component parts Keywords: načrtovanje zdravstvenega osebja, zdravljenje raka, paliativna oskrba, incidenca, umrljivost, napovedovanje
Published in DiRROS: 22.01.2026; Views: 568; Downloads: 373
 Full text (333,54 KB)
This document has many files! More... |
2. Poročilo Državnega programa obvladovanja raka za leto 2024Sonja Tomšič, Janez Žgajnar, Katarina Plantosar, Amela Duratović Konjević, Joka Kosmina, Branko Zakotnik, 2025, published professional conference contribution Keywords: javno zdravje, preventivni programi, onkologija
Published in DiRROS: 11.09.2025; Views: 808; Downloads: 299
Full text (89,21 KB) |
3. Votrient (pazopanib) : spremljevalni vodnik za zdravljenjeBreda Škrbinc, 2013, dictionary, encyclopaedia, lexicon, manual, atlas, map Keywords: rak ledvic, tarčna zdravila, bolniki, onkološki bolniki, vodniki
Published in DiRROS: 03.09.2025; Views: 774; Downloads: 340
 Link to file |
4. Timski pristop k zdravljenju raka glave in vratuPrimož Strojan, Cvetka Grašič-Kuhar, Branko Zakotnik, 2025, dictionary, encyclopaedia, lexicon, manual, atlas, map Keywords: timska obravnava, stranski učinki, bolniki, zdravstveni nasveti
Published in DiRROS: 07.08.2025; Views: 981; Downloads: 330
Full text (1,04 MB) |
5. |
6. Trends in population-based cancer survival in SloveniaVesna Zadnik, Tina Žagar, Katarina Lokar, Sonja Tomšič, Amela Duratović Konjević, Branko Zakotnik, 2021, original scientific article Keywords: cancer burden, cancer survival, time trend, cancer registry
Published in DiRROS: 22.07.2024; Views: 1308; Downloads: 862
Full text (693,86 KB)
This document has many files! More... |
7. Poročilo državnega programa obvladovanja raka za leto 2023Sonja Tomšič, Janez Žgajnar, Katarina Plantosar, Amela Duratović Konjević, Katarina Torkar, Branko Zakotnik, 2024, published professional conference contribution Keywords: obvladovanje raka, državni program, onkologija
Published in DiRROS: 06.06.2024; Views: 1449; Downloads: 505
Full text (66,82 KB) |
8. Prognostic value of some tumor markers in unresectable stage IV oropharyngeal carcinoma patients treated with concomitant radiochemotherapyErika Šoba, Marjan Budihna, Alojz Šmid, Nina Gale, Hotimir Lešničar, Branko Zakotnik, Primož Strojan, 2015, original scientific article Abstract: The aim of the study was to investigate how the expression of tumor markers p21, p27, p53, cyclin D1, EGFR, Ki-67, and CD31 influenced the outcome of advanced inoperable oropharyngeal carcinoma patients, treated with concomitant radiochemotherapy. Patients and methods. The pretreatment biopsy specimens of 74 consecutive patients with inoperable stage IV oropharyngeal squamous cell carcinoma treated with concomitant radiochemotherapy were in retrospective study processed by immunochemistry for p21, p27, p53, cyclin D1, EGFR, Ki-67, and CD31. Disease-free survival (DFS) was assessed according to the expression of tumor markers. Results. Patients with a high expression of p21 (%10%), p27 (>50%), Ki-67 (>50%), CD31 (>130 vessels/mm2) and low expression of p53 (<10%), cyclin D1 (<10%) and EGFR (<10%) (favorable levels - FL) had better DFS than patients with a low expression of p21 (<10%), p27 (%50%), Ki-67 (%50%), CD31 (<130 vessels/mm2) and high expression of p53 (%10%), cyclin D1 (%10%) and EGFR (%10%) (unfavorable levels - UL). However, statistical significance in survival between FL and UL was achieved only for p27 and cyclin D1. DFS significantly decreased with an increasing number of markers with an unfavorable level per tumor (1%4 vs. 5%7) (78% vs. 32%, respectively; p = 0.004). The number of markers per tumor with UL of expression retained prognostic significance also in multivariate analysis. Conclusions. Statistical significance in survival between FL and UL emerged only for p27 and cyclin D1. The number of markers per tumor with UL of expression was an independent prognostic factor for an adverse outcome .
Keywords: oropharynx, radiochemotherapy, tumor markers
Published in DiRROS: 22.04.2024; Views: 1812; Downloads: 600
Full text (560,05 KB) |
9. Effectiveness of adjuvant trastuzumab in daily clinical practiceErika Matos, Branko Zakotnik, Cvetka Grašič-Kuhar, 2014, original scientific article Abstract: Background. Human epidermal growth factor receptor 2 (HER2) positive breast cancer is an entity with aggressive behaviour. One year of adjuvant trastuzumab significantly improves the disease free survival in the range of 40-50% and reduces the risk of dying from HER2 positive breast cancer by one third. Adjuvant treatment with trastuzumab became available in Slovenia in 2005 and the aim of this study is to explore, if the exceptional results reported in adjuvant clinical trials are achieved also in daily clinical practice. Patients and methods. An analysis of tumour and patient characteristics, type of treatment and outcome (relapse free and overall survival) of 313 patients (median age 52 years) treated at the Institute of Oncology Ljubljana in years 2005-2009 was performed. Results. Median follow-up was 4.4 years. Sixty-one patients relapsed and 24 died. Three and four years relapse free survival was 84.2% and 80.8% and the overall survival was 94.4% and 92.5%, respectively. Independent prognostic factors for relapse were tumour grade (HR 2.10; 95% CI 1.07-4.14; p = 0.031) and nodal stage (HR 1.35; 1.16-1.56; p < 0.0001) and for the overall survival nodal stage only (HR 1.36; 1.05-1.78; p = 0.021). Conclusions. The outcome in patients with adjuvant trastuzumab in daily clinical practice, treated by medical oncologists, is comparable to results obtained in international adjuvant studies.
Keywords: breast cancer, trastuzumab, adjuvant, clinical practice
Published in DiRROS: 11.04.2024; Views: 2013; Downloads: 759
Full text (549,44 KB) |
10. |
